Acyclovir
Neonatal

Neonatal

Herpes Simplex Infections

≤32 wks PMA and <1200 g

20 mg/kg/dose IV q12h in consultation with ID

>32 wks PMA and ≥1200 g
  • 20 mg/kg/dose IV q8h x 21 days for disseminated or CNS infections
  • 14 days is used for isolated skin, eye and mouth disease

Antiviral suppressive therapy (after initial IV treatment of HSV disease with CNS involvement)

300mg/m2/dose PO q8h for 6 months